Trastuzumab and bevacizumab biosimilars enter the US market
For a long time, Roche’s three drugs, Rituxan, Herceptin and Avastin, dominated the global market. However, on July 18, their competitors appeared – Amgen and Allergan introduced the biosimilars of Herceptin preparations for the treatment of HER2-positive breast cancer and Avastin for the treatment of colorectal cancer to the USA, which threatened the total sales…